ParkA. 10 Ideas Changing the World Right Now. Time Magazine, 2009Mar23.
7.
BasikM, Aguilar-MahechaA, RousseauC, DiazZ, TejparS, SpatzA, et al.Biopsies: Next-generation biospecimens for tailoring therapy. Nat Rev Clin Oncol, 2013; 10:437–450.
8.
ZikaE, PaciD, BraunA, Rijkers-DefrasneS, DeschenesM, FortierI, et al.A European survey on biobanks: Trends and issues. Public Health Genomics, 2011; 14:96–103.
9.
HendersonGE, CadiganRJ, EdwardsTP, ConlonI, NelsonAG, EvansJP, et al.Characterizing biobank organizations in the U.S.: Results from a national survey. Genome Med, 2013; 5:3.
10.
ArdiniMA, PanH, QinY, CooleyPC. Sample and data sharing: Observations from a central data repository. Clin Biochem, 2014; 47:252–257.
11.
VaughtJ, RogersJ, MyersK, LimMD, LockhartN, MooreH, et al.An NCI Perspective on Creating Sustainable Biospecimen Resources. J Natl Cancer Inst Monogr, 2011; 42:1–7.
12.
VaughtJB, HendersonMK, ComptonCC. Biospecimens and biorepositories: From afterthought to science. Cancer Epidemiol Biomarkers Prev, 2012; 21:253–255.
13.
HofmanP, BrechotC, ZatloukalK, DagherG, ClementB. Public-private relationships in biobanking: A still underestimated key component of open innovation. Virchows Arch, 2014; 464:3–9.
14.
ISBER. International Society of Biological and Environmental Repositories. ISBER, 2013May27. www.isber.org
15.
ESBB. European, Middle Eastern & African Society for Biopreservation & Biobanking. ESBB, 2013September28. www.esbb.org/.
16.
P3G. Public Population Project in Genomics and Society. 2013. www.p3g.org.
ISBER. 2012 Best practices for repositories: Collection, storage, retrieval, and distribution of biological material for research. Biopreserv Biobank, 2012; 10:79–161.
VaughtJ, RogersJ, CarolinT, ComptonC. Biobankonomics: Developing a sustainable business model approach for the formation of a human tissue biobank. J Natl Cancer Inst Monogr, 2011; 42:24–31.
25.
PaltooDN, et.al, on behalf of NIH Genomic Data Sharing Covernance Committees. Data use under the NIH GWAS Data Sharing Policy and future directions. Nat Genet, 2014; 46:934–938.
26.
BudimirD, PolasekO, MarusicA, KolcicI, ZemunikT, BoraskaV, et al.Ethical aspects of human biobanks: A systematic review. Croat Med J, 2011; 52:262–279.
27.
LeBlancJ, DeeS, BraunL, DaudtH, CheahS, WatsonPH. Impact of a permission to contact (PTC) platform on biobank enrollment and efficiency. Biopreserv Biobank, 2013; 11:144–148.
28.
Matharoo-BallB, WoosltonC, ElliottJ, LockeT, TaylorS, ThomsonB. Patient public involvement (PPI) in consenting for biobanks. Biopreserv Biobank, 2013; 11:A-4 ELSI 06.
29.
WolfSM, CrockBN, VanNB, LawrenzF, KahnJP, BeskowLM, et al.Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genet Med, 2012; 14:361–384.
30.
WolfSM. The past, present, and future of the debate over return of research results and incidental findings. Genet Med, 2012; 14:355–357.
31.
BledsoeMJ, ClaytonEW, McGuireAL, GrizzleWE, O'RourkePP, ZepsN. Return of research results from genomic biobanks: A call for data. Genet Med, 2013; 15:159–160.
32.
BledsoeMJ, ClaytonEW, McGuireAL, GrizzleWE, O'RourkePP, ZepsN. Return of research results from genomic biobanks: Cost matters. Genet Med, 2013; 15:103–105.
Cambon-ThomsenA, ThorissonGA, MabileL. The role of a bioresource research impact factor as an incentive to share human bioresources. Nat Genet, 2011; 43:503–504.
MatzkeEAM, O'DonoghueS, BarnesRO, DaudtH, CheahS, SuggitA, et al.Certification for biobanks: The program developed by the Canadian Tumour Repository Network (CTRNet). Biopreserv Biobank, 2012; 10:426–432.
41.
MooreHM, KellyAB, JewellSD, McShaneLM, ClarkDP, GreenspanR, et al.Biospecimen reporting for improved study quality (BRISQ). Biopreserv Biobank, 2011; 9:57–70.
42.
BetsouF, LehmannS., AshtonG, BarnesM, BensonEE, CoppolaD, et al.Standard preanalytical coding for biospecimens: Defining the sample PREanalytical code. Cancer Epidemiol Biomarker Prev, 2010; 19:1004–1011.
43.
LehmannS, GuadagniF, MooreH, AshtonG, BarnesM, BensonE, et al.Standard preanalytical coding for biospecimens: Review and implementation of the Sample PREanalytical Code (SPREC). Biopreserv Biobank, 2012; 10:366–374.
44.
ColeA, CheahS, DeeS, HughesS, WatsonPH. Biospecimen use correlates with emerging techniques in cancer research: Impact on planning future biobanks. Biopreserv Biobank, 2012; 10:518–525.
45.
HughesSE, BarnesR.O., WatsonP. Biospecimen use in cancer research over two decades. Biopres Biobank, 2010; 8:89–97.
46.
Simeon-DubachD, BurtAD, HallPA. Quality really matters: The need to improve specimen quality in biomedical research. J Pathol, 2012; 228:431–433.
47.
Simeon-DubachD, BurtAD, HallPA. Quality really matters: The need to improve specimen quality in biomedical research. Histopathology, 2012; 61:1003–1005.
Simeon-DubachD, MooreHM. BIO comes into the cold to adopt BRISQ. Biopreserv Biobank, 2014; 12:223–224.
50.
McShaneLM, HayesDF. Publication of tumor marker research results: The necessity for complete and transparent reporting. J Clin Oncol, 2012; 30:4223–4232.
51.
Simeon-DubachD, PerrenA. Better provenance for biobank samples. Nature, 2011; 475:454–455.